Schizophrenia News and Research RSS Feed - Schizophrenia News and Research

Schizophrenia is a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. While significant progress has been made in understanding the disease and developing treatments, there remains a significant unmet medical need. More than 50% of patients switch their medication in a given year due to either poor response or the experience of adverse events.
Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]
Suicidal ideation link to suicide strong in schizophrenia spectrum disorders

Suicidal ideation link to suicide strong in schizophrenia spectrum disorders

The association between suicidal ideation and later suicide is much stronger in patients with schizophrenia spectrum psychosis than in those with mood disorders, show results of a systematic meta-analysis. [More]
Scientists receive NARSAD Distinguished Investigator Grants for mental health research

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

The Brain & Behavior Research Foundation today announced the award of NARSAD Distinguished Investigator Grants valued at $1.5 million to 15 scientists, who are full professors or the equivalent, conducting innovative projects in diverse areas of neurobiological and behavioral research. [More]

Schizophrenia symptom severity predicts atypical antipsychotic benefit

Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry. [More]

UM researchers develop novel, family-focused, culturally-informed treatment for schizophrenia

Researchers at the University of Miami have developed a family-focused, culturally-informed treatment for schizophrenia (CIT-S). The program is one of the first to incorporate elements of the patient's cultural background as part of therapy. [More]
Cue processing altered in siblings of schizophrenia patients

Cue processing altered in siblings of schizophrenia patients

The siblings of patients with schizophrenia have altered activity in the ventral striatum during reward anticipation and receipt, a study shows. [More]
Mortality gap persists for elderly men with severe mental disorders

Mortality gap persists for elderly men with severe mental disorders

The excess mortality experienced by men with severe mental disorders, compared with their mentally healthy peers, does not decrease with age, Australian research shows. [More]
Accumulated environmental risks have substantial impact on schizophrenia

Accumulated environmental risks have substantial impact on schizophrenia

Accumulation of environmental risk factors has a “huge” effect on age at schizophrenia onset, German researchers report. [More]
Paternal age increases schizophrenia risk independently of IQ

Paternal age increases schizophrenia risk independently of IQ

Being born to an older father increases the risk of developing a schizophrenia spectrum disorder in adulthood but has no effect on premorbid IQ, say researchers from Denmark. [More]
Physical health management below par in schizophrenia patients

Physical health management below par in schizophrenia patients

The diagnosis and treatment of physical ailments in patients with schizophrenia falls below acceptable standards, shows a national audit of patients in England and Wales. [More]
Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. [More]
UCSD researchers validate EEG test to study, treat schizophrenia

UCSD researchers validate EEG test to study, treat schizophrenia

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options. [More]
Teen binge drinking effects may last a lifetime, suggests UMass Amherst study

Teen binge drinking effects may last a lifetime, suggests UMass Amherst study

Binge drinking can have lasting effects on brain pathways that are still developing during adolescence, say neuroscience researcher Heather N. Richardson and her colleagues at the University of Massachusetts Amherst and Louisiana State University. [More]
Study finds that mental health disorders double heart disease, stroke risks

Study finds that mental health disorders double heart disease, stroke risks

People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress. [More]
Dietary cocoa flavanols can reverse age-related memory decline in healthy older adults

Dietary cocoa flavanols can reverse age-related memory decline in healthy older adults

Dietary cocoa flavanols—naturally occurring bioactives found in cocoa—reversed age-related memory decline in healthy older adults, according to a study led by Columbia University Medical Center scientists. [More]
Engineered cells reveal changes associated with learning, memory and reward

Engineered cells reveal changes associated with learning, memory and reward

Scientists have created cells with fluorescent dyes that change color in response to specific neurochemicals. By implanting these cells into living mammalian brains, they have shown how neurochemical signaling changes as a food reward drives learning, they report in Nature Methods online October 26. [More]

Genetics underpin bullying victimisation influence on paranoia

Bullying victimisation in childhood may indicate genetic risk for later psychosis, rather than being an environmental trigger, say UK researchers. [More]

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers. [More]
Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. [More]